Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Copper ion chelation refers to the process of selectively binding and removing copper ions, most commonly the oxidized Cu2+ (cupric ion), from biological systems using chelating agents. Copper is an essential trace element involved as a cofactor in various enzymes and in cellular processes including cytochrome c oxidase function, antioxidant defense (via superoxide dismutase), and regulation of growth factor pathways[4][5][8]. However, excess copper is toxic and can catalyze harmful oxidative reactions, disrupt protein structure through mis-metallation, and promote aggregation of proteins such as amyloid-β in neurodegenerative diseases[4][5]. Chelation therapy is used to restore copper homeostasis in diseases such as Wilson disease (characterized by copper overload) and is under investigation in oncology for its role in inhibiting copper-dependent angiogenesis and tumor proliferation[6][8]. Several drugs, including tetrathiomolybdate and D-penicillamine, are approved or in clinical use for copper chelation, and novel, more selective chelators are being developed to minimize off-target effects and avoid depletion of copper required for physiological functions[1][2][5]. Chelating agents vary in specificity, with a goal of achieving high affinity for pathogenic (redox-active, loosely bound) copper pools without disturbing essential biological copper[1][2]. Safety concerns include the potential for copper deficiency, impacts on other metals, and organ toxicity. Caveat: Copper ion chelation is not itself a discrete molecular entity, receptor, or protein but rather a *therapeutic mechanism* or process. Therefore, the “target” refers to a chemical species (Cu2+ ion) and its pathological pool. It cannot be strictly classified alongside proteins, enzymes, or receptors, and the precise biological effects depend on the specificity of the chelator and disease context[1][2][3][5][8].
Chelation and sequestration of free or loosely bound copper(II) ions (Cu2+); Prevention of copper-induced oxidative damage; Inhibition of copper-dependent angiogenesis; Modulation of copper-dependent enzyme and protein activity
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Copper ion chelation.